



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Commentary



## A commentary on “Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings” [Int. J. Surg. 2020; 79:143–153]

Since December 1, 2019, a cluster of pneumonia of unknown etiology, now known as coronavirus disease-2019 (COVID-19), has been reported in Wuhan, Hubei province, China [1]. The disease has developed a severe pandemic affecting over 200 countries, areas or territories. Without a therapeutic vaccine or specific antiviral drugs, early detection and isolation becomes essential against novel coronavirus. We read with great interest the publication by Abbasi-Oshaghi and colleagues [2], “Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings”. This review focuses on currently available information on the etiology, clinical symptoms, diagnosis, and mechanism of action of COVID-19. We would like to share our opinion on this valuable work.

In our experience, some patients with likely COVID-19 infection may have initial negative reverse transcriptase (RT) polymerase chain reaction (PCR) results. Reasons for false negative RT-PCR may include insufficient cellular material for detection and improper extraction of nucleic acid from clinical materials. Asymptomatic cases with COVID-19 are of great concern. They contribute to the spread of COVID-19, with similar transmission rates as symptomatic patients, while the virus replicates in their lower respiratory tract resulting in radiological evidence of infection. Reports show that asymptomatic cases with normal chest CT have shorter periods from diagnosis to being COVID-19 negative than asymptomatic cases with positive chest CT [3,4]. COVID-19 should be considered among cases with CT abnormalities even when there are no other symptoms.

The CT imaging of COVID-19 infection should be differentiated with other virus pneumonias, such as influenza virus, parainfluenza virus, respiratory syncytial virus, and adenovirus. Adenovirus pneumonia lesions had higher density, more consolidations, and fewer subpleural lesions. Respiratory syncytial virus and parainfluenza virus pneumonia lesions were mostly distributed along the bronchial tree with a thickened bronchial wall. Influenza viruses could cause grid-like changes in the lungs. In addition, it should be differentiated from bacterial pneumonia, mycoplasma pneumonia, and chlamydia pneumonia, and the density of pneumonia lesions caused by the latter pathogens is relatively higher. However, chest CT manifestations of pneumonia caused by different pathogens overlap, and COVID-19 pneumonia can be superimposed with pneumonia caused by other types of pathogens, presenting more serious and complex imaging manifestations, so epidemiological and etiological examination should be combined.

In summary, clinicians should consider COVID-19 in cases with positive chest CT findings, even without clinical symptoms. However, the diagnosis of COVID-19 pneumonia by CT imaging alone is not sufficient enough, especially in the case of coinfection with other

pathogens. Therefore, early chest CT screening and timely follow-up, combined with corresponding pathogen detection, is a feasible clinical protocol. On the other hand, the exact place of chest CT is for staging the COVID-19 disease as mild, moderate, and severe, instead of being a screening tool.

### Ethical approval

No Ethical Approval was not given.

### Sources of funding

None.

### Author contribution

**Guosheng Huang:** Writing - original draft, **Dawei Zheng:** Language edition.

### Trial registry number

N.A.

### Guarantor

Dawei Zheng.

### Declaration of competing interest

The authors declare that they have no conflict of interest.

### References

- [1] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *Lancet* 395 (2020) 497–506.
- [2] E. Abbasi-Oshaghi, F. Mirzaei, F. Farahani, I. Khodadadi, H. Tayebinia, Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings, *Int. J. Surg.* 79 (2020) 143–153.
- [3] A. Kronbichler, D. Kresse, S. Yoon, K.H. Lee, M. Effenberger, J.I. Shin, Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis, *Int. J. Infect. Dis.* 98 (2020) 180–186.
- [4] V.M. Tsikala, E. Atalla, M. Kalligeros, E.K. Mylonas, F. Shehadeh, E. Mylonakis, Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis, *Clin. Radiol.* 75 (2020) 876.e33–876.e39.

DOI of original article: <https://doi.org/10.1016/j.ijso.2020.05.018>.

<https://doi.org/10.1016/j.ijso.2021.105931>

Received 13 March 2021; Accepted 22 March 2021

Available online 1 April 2021

1743-9191/© 2021 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Dawei Zheng  
Department of Respiratory, Nanyang Central Hospital, Henan, 473000,  
China

Guosheng Huang\*

Department of Thoracic Surgery, The First Affiliated Hospital of Nanyang  
Medical College, Henan, 473000, China

\* Corresponding author.  
E-mail address: [intmedsci@163.com](mailto:intmedsci@163.com) (G. Huang).